Answers are grounded in this paper and cite their sources.
The efficacy and safety of modified-release methylphenidate (MPH-MR) in the treatment of attention-deficit/hyperactivity disorder (ADHD) have been shown in both pediatric and adult Caucasian patients. The objective of this study was to assess the efficacy and safety of MPH-MR in Chinese children and adolescents with ADHD. MICCA was a randomized, double-blind, placebo-controlled trial conducted at 19 sites in China from September 2018 to July 2021. The study enrolled children and adolescents aged 6 to < 18 years with a primary diagnosis of ADHD according to the Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition (DSM-5). Patients were randomized 1:1 to once-daily MPH-MR (10–60 mg) or placebo. The study included an up-titration phase of up to 5 weeks and a dose maintenance phase of 4 weeks. The primary efficacy endpoint was the change in the ADHD Rating Scale-IV (ADHD-RS-IV) total score from baseline to the end of the maintenance phase (EoM). Secondary endpoints included the change from baseline to EoM in Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) total score, and Clinical Global Impression-Improvement (CGI-I) scores at EoM. Safety assessments included treatment-emergent adverse events (TEAEs) and vital signs. A total of 221 patients were randomized (MPH-MR: n = 110; placebo: n = 111). The change in the ADHD-RS-IV total score from baseline to EoM was significantly greater for MPH-MR versus placebo, with a least squares (LS) mean (95% confidence interval [CI]) treatment difference of − 4.6 (− 6.92, − 2.30) (p < 0.001). The mean (95% CI) treatment difference for the WFIRS-P total score change from baseline to EoM also significantly favored MPH-MR over placebo (− 6.46 [− 10.57, − 2.34]; p = 0.002). The CGI-I score at EoM was significantly lower in the MPH-MR group compared to the placebo group (2.2 vs 2.5; p = 0.002). Treatment-emergent adverse events were reported for 74 (67.3%) patients in the MPH-MR group and 55 (49.1%) patients in the placebo group. Most TEAEs were mild to moderate in severity. The most common TEAEs for MPH-MR were decreased appetite, nausea and upper respiratory tract infection. Treatment-emergent adverse events leading to study drug discontinuation/study withdrawal were reported in 4 (3.6%) patients in the MPH-MR group and 1 (0.9%) patient in the placebo group. No clinically relevant changes in vital signs were observed during the study. Modified-release methylphenidate was superior to placebo in improving ADHD symptoms and functioning in Chinese pediatric patients with ADHD. Modified-release methylphenidate had a good safety and tolerability profile. Trial Registration http://www.chinadrugtrials.org.cn/ Identifier: CTR20180056 (registered on 21 May 2018). Attention-deficit/hyperactivity disorder (ADHD) is characterized by inattention and/or hyperactivity/impulsivity. Modified-release methylphenidate (MPH-MR) is a medication approved in several countries for the treatment of ADHD in children aged ≥ 6 years and adults (common brand names: Medikinet® XL and Medikinet® MR). The efficacy and safety of MPH-MR have been demonstrated in Caucasian children, adolescents and adults with ADHD. This clinical trial investigated the efficacy and safety of MPH-MR in Chinese children and adolescents with ADHD. We randomly assigned 221 patients to receive either once-daily MPH-MR or placebo. The study included an initial dose adjustment phase (up to 5 weeks) during which the optimal daily dose for each patient was determined based on treatment response and tolerability. The individual daily dose (10–60 mg) was then maintained for 4 weeks. Neither the patients nor the investigators knew which drug the patient received. The primary efficacy measure was the ADHD Rating Scale-IV (ADHD-RS-IV), a questionnaire completed by the parents to rate the frequency of ADHD symptoms. At the end of the maintenance phase, patients treated with MPH-MR showed a greater reduction in ADHD symptoms compared to patients treated with placebo based on ADHD-RS-IV scores. In addition, patients receiving MPH-MR showed greater improvements in daily functioning compared to patients receiving placebo. Modified-release methylphenidate had a good safety and tolerability profile. Common adverse events included decreased appetite, nausea and upper respiratory tract infection. In summary, our findings show that MPH-MR is effective and has good safety and tolerability in treating ADHD in Chinese children.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: